<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000967</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 153</org_study_id>
    <secondary_id>11128</secondary_id>
    <nct_id>NCT00000967</nct_id>
  </id_info>
  <brief_title>The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children</brief_title>
  <official_title>Safety and Tolerance of Zidovudine and Interferon-Alpha in HIV-Infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      PRIMARY: To determine the maximum tolerated dose of interferon-alfa (IFN-A) alone and in&#xD;
      combination with zidovudine (AZT); to assess the safety and tolerance of IFN-A alone and in&#xD;
      combination with AZT.&#xD;
&#xD;
      SECONDARY: To evaluate the effect of combination IFN-A and AZT on immunologic and virologic&#xD;
      parameters; to determine whether the pharmacokinetic parameters of AZT are modified by the&#xD;
      subcutaneous administration of IFN-A.&#xD;
&#xD;
      AZT is effective in suppressing the progression of HIV infection in patients without symptoms&#xD;
      or with AIDS or AIDS-related complex (ARC). However, use of AZT is limited by its frequent&#xD;
      toxicity, which sometimes relates to the amount of drug given. Thus, a combination treatment&#xD;
      of two drugs that work together may provide more effective and safer treatment. IFN-A is a&#xD;
      drug that has antiviral effects and may work well with AZT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZT is effective in suppressing the progression of HIV infection in patients without symptoms&#xD;
      or with AIDS or AIDS-related complex (ARC). However, use of AZT is limited by its frequent&#xD;
      toxicity, which sometimes relates to the amount of drug given. Thus, a combination treatment&#xD;
      of two drugs that work together may provide more effective and safer treatment. IFN-A is a&#xD;
      drug that has antiviral effects and may work well with AZT.&#xD;
&#xD;
      The study is being conducted in three stages. In Cohort A (IFN-A alone), four patients&#xD;
      receive IFN-A; subsequent four-patient cohorts receive doses escalated in increments. If 50&#xD;
      percent or more of patients at any dose level experience grade 2 or better toxicity, doses in&#xD;
      subsequent cohorts are escalated. If grade 3 or 4 toxicity is seen in one patient at a given&#xD;
      dose level, two additional patients are enrolled at that level. Treatment is given&#xD;
      subcutaneously (under the skin, with a needle), 3 times per week for 12 weeks. The MTD is&#xD;
      defined as the dose level immediately below that at which 50 percent or more of patients&#xD;
      experience grade 3 or 4 toxicity. In Cohort B (combination IFN-A plus AZT), patients who&#xD;
      complete treatment in Cohort A continue on the same dose of IFN-A, and a low, middle, or high&#xD;
      dose of AZT is added. In Cohort C, four newly assigned patients who have been on a stable&#xD;
      prescribed dose of AZT of at least 90 mg/m2 for 6 weeks are treated at each of the same dose&#xD;
      combinations as those in Cohort B. Treatment is given for 12 weeks. IFN-A is given&#xD;
      subcutaneously 3 times a week and AZT is given orally every 6 hours. Dose levels of both&#xD;
      drugs are increased until 50 percent or more of patients experience grade 3 or 4 toxicity in&#xD;
      any dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>52</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-2a</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Recommended:&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosol ribavirin for short-term treatment of acute respiratory syncytial virus (RSV).&#xD;
&#xD;
          -  Immunization according to the current recommendations of the Advisory Committee for&#xD;
             Immunization Practice.&#xD;
&#xD;
          -  IVIG. Systemic ketoconazole, acyclovir, or oral nystatin for acute therapy.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV infection. Patients with proven resistance to AZT are also eligible.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosol ribavirin.&#xD;
&#xD;
        Required:&#xD;
&#xD;
        Cohort C treatment:&#xD;
&#xD;
          -  Stable prescribed dose of zidovudine (AZT) &gt;= 90 mg/m2 for at least 6 weeks prior to&#xD;
             study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded: AIDS or class P-2B, D, or&#xD;
        E symptomatic infection.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Hepatotoxic or neurotoxic drugs, immunosuppressants, or antiseizure medication.&#xD;
             Ketoconazole, fluconazole, and acyclovir for prophylaxis. Immunomodulators (other than&#xD;
             IVIG). Experimental drugs.&#xD;
&#xD;
        Cohort A patients:&#xD;
&#xD;
          -  AZT for clinical indications.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretroviral agents (including didanosine (ddI), dideoxycytidine (ddC), or&#xD;
             soluble CD4) within 1 month of study entry. Systemic ribavirin administered for&#xD;
             retroviral therapy within 2 months of study entry.&#xD;
&#xD;
          -  Immunomodulating agents including interferon, isoprinosine, interleukin-2, or&#xD;
             lymphocyte transfusions within 4 weeks of study entry.&#xD;
&#xD;
          -  RBC transfusion within 4 weeks prior to study entry.&#xD;
&#xD;
        Alcohol or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diaz C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Yogev R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Cook County Hosp.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane/LSU Maternal/Child CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMC, Div. of Ped Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med. Ctr., Dept. of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hosp. Ram√≥n Ruiz Arnau, Dept. of Peds.</name>
      <address>
        <city>Bayamon</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Diaz C, Yogev R, Culnane M, Rogers A, Van Dyke R, Fenton T. ACTG 153: a multicenter phase I study of alpha-interferon in HIV infected children. AIDS Clinical Trials Group. Int Conf AIDS. 1994 Aug 7-12;10(1):79 (abstract no 269B)</citation>
  </reference>
  <reference>
    <citation>Clemente D, Yogev R, Culnane M, Rogers A, Van Dyke R, Hetherington S, Fenton T. ACTG 153: phase I, open-label; dose escalating study of interferon-alpha alone and in combination with zidovudine in children with early HIV disease. Program Abstr Intersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7:35</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Interferon Type I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

